Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15216069 | 0.93 | CYP2C9 (0.61) | CYP2C9HSD17B1HSD17B2MAPTALDH1A1 | |
| SCHEMBL16018454 | 0.92 | CYP2C9 (0.59) | CYP2C9HSD17B1HSD17B2MAPTALDH1A1 | |
| SCHEMBL1507721 | 0.88 | CYP2C9 (0.53) | CYP2C9HSD17B1HSD17B2MAPTALDH1A1 | |
| Fluorescin SCHEMBL31164673 | 0.84 | CYP2C9 (0.71) | CYP2C9MAPTALDH1A1TSHRCASP1 | |
| Fluorescin SCHEMBL31214151 | 0.84 | CYP2C9 (0.71) | CYP2C9MAPTALDH1A1TSHRCASP1 | |
| Fluorescin SCHEMBL29370997 | 0.84 | CYP2C9 (0.71) | CYP2C9MAPTALDH1A1TSHRCASP1 | |
| SCHEMBL12037609 | 0.84 | CYP2C9 (0.71) | CYP2C9MAPTALDH1A1CASP1KDM4E | |
| Fluorescin SCHEMBL27403 | 0.84 | CYP2C9 (0.71) | CYP2C9MAPTALDH1A1TSHRCASP1 | |
| Fluorescin SCHEMBL31164674 | 0.84 | CYP2C9 (0.71) | CYP2C9MAPTALDH1A1TSHRCASP1 | |
| SCHEMBL4292264 | 0.82 | CYP2C9 (1.00) | CYP2C9MAPTALDH1A1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227491-B2 | Fluorescent reactive dyes, process for the production thereof and their use | DyStar Coulors Distribution GmbH (DE) | 2019-03-12 | — | — | US | disclosed |
| US-20180194943-A1 | FLUORECENT REACTIVE DYES, PROCESS FOR THE PRODUCTION THEREOF AND THEIR USE | DYSTAR COLOURS DISTRIBUTION GMBH (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20180194943-A1 | FLUORECENT REACTIVE DYES, PROCESS FOR THE PRODUCTION THEREOF AND THEIR USE | DYSTAR COLOURS DISTRIBUTION GMBH (DE) | 2018-07-12 | — | — | US | disclosed |
| WO-2015158574-A1 | FLUORESCENT REACTIVE DYES, PROCESS FOR THE PRODUCTION THEREOF AND THEIR USE | DYSTAR COLOURS DISTRIBUTION GMBH (DE) | 2015-10-22 | — | — | WO | disclosed |
| EP-2933296-A1 | Fluorescent reactive dyes, process for the production thereof and their use | DyStar Colours Distribution GmbH (DE) | 2015-10-21 | — | — | EP | disclosed |
| EP-2305246-B1 | Tumor necrosis factor inhibitors | UNIV PENNSYLVANIA (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2305246-B1 | Tumor necrosis factor inhibitors | UNIV PENNSYLVANIA (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2305246-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2298295-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298295-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-1845970-A4 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1845970-A2 | TUMOR NECROSIS FACTOR INHIBITORS | Ception Therapeutics, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006083970-A2 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006083869-A2 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | CYP2C9 4775/4885HSD17B1 2706/4885HSD17B2 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.